{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:51:09Z","timestamp":1762249869176},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03432-w","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T10:03:12Z","timestamp":1672048992000},"page":"1373-1381","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials"],"prefix":"10.1007","volume":"55","author":[{"given":"Yuhan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maifen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"3432_CR1","first-page":"47","volume":"47","author":"L Giovanna","year":"2021","unstructured":"Giovanna L, Massimo V (2021) FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease. Eur Heart J 47:47","journal-title":"Eur Heart J"},{"issue":"2","key":"3432_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.ajkd.2021.02.324","volume":"78","author":"VS Sridhar","year":"2021","unstructured":"Sridhar VS, Liu H, Cherney D (2021) Finerenone\u2014a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease. Am J Kidney Dis 78(2):309\u2013311","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"3432_CR3","first-page":"713","volume":"325","author":"A Slomski","year":"2021","unstructured":"Slomski A (2021) Finerenone for patients with CKD and type 2 diabetes. JAMA, J Am Med Assoc 325(8):713","journal-title":"JAMA, J Am Med Assoc"},{"key":"3432_CR4","doi-asserted-by":"crossref","unstructured":"Katayama S, D Yamada, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications, 2017, 31(4):758\u2013765.","DOI":"10.1016\/j.jdiacomp.2016.11.021"},{"issue":"9","key":"3432_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884\u2013894","journal-title":"JAMA"},{"issue":"24","key":"3432_CR6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263","journal-title":"N Engl J Med"},{"issue":"23","key":"3432_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229","journal-title":"N Engl J Med"},{"issue":"4","key":"3432_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"S Katayama","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M et al (2017) A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications 31(4):758\u2013765","journal-title":"J Diabetes Complications"},{"key":"3432_CR9","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u20132114.","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"3432_CR10","doi-asserted-by":"crossref","unstructured":"Sato N, Ajioka M, Yamada T, et al. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease. Circ J. 2016;80(5):1113\u20131122.","DOI":"10.1253\/circj.CJ-16-0122"},{"issue":"31","key":"3432_CR11","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463","journal-title":"Eur Heart J"},{"key":"3432_CR12","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"3432_CR13","unstructured":"Higgins J, Thomas J, eds et al. Cochrane Handbook for systematic reviews of interventions version 6.2, 2021. Accessed April, 25, 2021."},{"issue":"1","key":"3432_CR14","first-page":"1","volume":"17","author":"SJ Allison","year":"2020","unstructured":"Allison SJ (2020) Finerenone in chronic kidney disease. Nat Rev Nephrol 17(1):1\u20131","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"3432_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13318-020-00610-y","volume":"45","author":"R Heinig","year":"2020","unstructured":"Heinig R, Gerisch M, Bairlein M et al (2020) Results from drug\u2013drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet 45(4):433\u2013444","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"3432_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","volume":"22","author":"JS Rico-Mesa","year":"2020","unstructured":"Rico-Mesa JS, White A, Ahmadian-Tehrani A et al (2020) Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep 22(11):140","journal-title":"Curr Cardiol Rep"},{"key":"3432_CR17","doi-asserted-by":"crossref","unstructured":"Matthias N, AF Hernandez, Frank R. Finerenone in heart failure: walking a fine line. Euro Heart J, 2016(27):2115\u20132117.","DOI":"10.1093\/eurheartj\/ehw155"},{"issue":"2","key":"3432_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","volume":"78","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Bakris GL, Pitt B et al (2021) Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78(2):142\u2013152","journal-title":"J Am Coll Cardiol"},{"key":"3432_CR19","doi-asserted-by":"crossref","unstructured":"Yanhuan, Feng, Xiaoxi, et al. Finerenone for albuminuria in patients with diabetic nephropathy. JAMA, 2016, 315(3):305\u20136.","DOI":"10.1001\/jama.2015.15996"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03432-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T13:12:01Z","timestamp":1681564321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03432-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["3432"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03432-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}